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Summary
Background Mutant mouse models suggest that the chloride channel ClC-2 has functions in ion and water 
homoeostasis, but this has not been confi rmed in human beings. We aimed to defi ne novel disorders characterised by 
distinct patterns of MRI abnormalities in patients with leukoencephalopathies of unknown origin, and to identify the 
genes mutated in these disorders. We were specifi cally interested in leukoencephalopathies characterised by white 
matter oedema, suggesting a defect in ion and water homoeostasis.
Methods In this observational analytical study, we recruited patients with leukoencephalopathies characterised by 
MRI signal abnormalities in the posterior limbs of the internal capsules, midbrain cerebral peduncles, and middle 
cerebellar peduncles from our databases of patients with leukoencephalopathies of unknown origin. We used exome 
sequencing to identify the gene involved. We screened the candidate gene in additional patients by Sanger sequencing 
and mRNA analysis, and investigated the functional eff ects of the mutations. We assessed the localisation of ClC-2 
with immunohistochemistry and electron microscopy in post-mortem human brains of individuals without 
neurological disorders.
Findings Seven patients met our inclusion criteria, three with adult-onset disease and four with childhood-onset 
disease. We identifi ed homozygous or compound-heterozygous mutations in CLCN2 in three adult and three 
paediatric patients. We found evidence that the CLCN2 mutations result in loss of function of ClC-2. The remaining 
paediatric patient had an X-linked family history and a mutation in GJB1, encoding connexin 32. Clinical features 
were variable and included cerebellar ataxia, spasticity, chorioretinopathy with visual fi eld defects, optic neuropathy, 
cognitive defects, and headaches. MRI showed restricted diff usion suggesting myelin vacuolation that was confi ned 
to the specifi ed white matter structures in adult patients, and more diff usely involved the brain white matter in 
paediatric patients. We detected ClC-2 in all components of the panglial syncytium, enriched in astrocytic endfeet at 
the perivascular basal lamina, in the glia limitans, and in ependymal cells. 
Interpretation Our observations substantiate the concept that ClC-2 is involved in brain ion and water homoeostasis. 
Autosomal-recessive CLCN2 mutations cause a leukoencephalopathy that belongs to an emerging group of disorders 
aff ecting brain ion and water homoeostasis and characterised by intramyelinic oedema.
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Epigenetic Networks in Cognitive Dysfunction (GENCODYS) Project (funded by the European Union Framework 
Programme 7).
Introduction
ClC-2 is a chloride channel that is almost ubiquitously 
expressed in the human body.1 It is present in plasma 
membranes and is activated by hyperpolarisation, acidic 
extracellular pH, and osmotic cell swelling.1–4 Its 
functions in human physiology are a matter of debate. 
Roles in gastric acid secretion, lung development and 
function, and nephronogenesis have been suggested, but 
not confi rmed.1,5 Information about the localisation of 
ClC-2 within the brain comes from rodent studies, which 
have detected ClC-2 in oligodendrocytes, astrocytes 
(especially in endfeet), and pyramidal and non-pyramidal 
neurons in the hippocampus.6,7 Evidence suggests that 
ClC-2 modulates postsynaptic responses to GABA by 
aff ecting intracellular chloride concentration in neurons8 
and that ClC-2 regulates neuronal excitability,9,10 but the 
physiological relevance of these fi ndings has not been 
confi rmed.
Physiological roles of proteins can be gleaned from 
diseases caused by mutations in their genes. No human 
disease has been unequivocally related to mutations in 
CLCN2, the gene encoding ClC-2. Heterozygous 
mutations in CLCN2 were described as a cause of 
idiopathic generalised epilepsies,11–17 but this fi nding was 
later refuted1,18 and the original paper was retracted.17 
Because mutant mice without functional ClC-2 have a 
leukoencephalopathy with intramyelinic oedema,5,6,19 
ClC-2 was proposed to have a role in brain ion and water 
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homoeostasis;5,6 however, this hypothesis has not been 
confi rmed in human beings. A known human disorder 
characterised by intramyelinic oedema is megalen-
cephalic leukoencephalopathy with subcortical cysts.20–22 
Mutations in MLC1 have been identifi ed in 75% of 
patients with this disorder.23,24 No mutations in CLCN2 
were reported in the patients without MLC1 mutations.25 
Recently, mutations in HEPACAM (also called 
GLIALCAM), which encodes the glial cell adhesion 
molecule (GlialCAM)—a putative auxiliary subunit of 
both ClC-2 and MLC126,27—were identifi ed in patients 
without MLC1 mutations.26 
We aimed to study patients with leukoencephalopathies 
of unknown origin to defi ne novel disorders characterised 
by distinct patterns of MRI abnormalities28 and identify the 
mutated genes. We were specifi cally interested in 
leukoencephalopathies with MRI evidence of intramyelinic 
oedema. When we identifi ed CLCN2 mutations in a group 
of such patients, we sought further evidence for ClC-2’s 
function in human physiology.
Methods
Study design and patients
In this observational analytical study, we used MRI 
criteria to recruit adult and paediatric patients from the 
Amsterdam and Paris leukoencephalopathy databases 
containing MRI images of patients with 
leukoencephalopathies of unknown origin submitted 
from all over the world. Patients with prominent signal 
abnormalities in the middle cerebellar peduncles, 
midbrain cerebral peduncles, and posterior limbs of the 
internal capsules were included in the study. 
We studied the MRI results of each patient and scored 
the appearance and distribution of signal abnormalities. 
We assessed apparent diff usion coeffi  cient (ADC) values 
in areas of abnormal signal. Signal intensity on T2-weighted 
and T1-weighted images and ADC values provide 
information on tissue microstructure. High ADC values 
indicate large water spaces; low ADC values indicate small 
water spaces. Because the study was multi-institutional, 
MRIs were done with diff erent pulse sequences on 
machines from diff erent vendors. Therefore, we used a 
robust cutoff  ADC value of 60×10−⁵ mm²/s, below which 
the diff usion was considered to be restricted. Subtle 
diff usion restriction could, therefore, have been missed.
We obtained approval from the insti tutional review 
boards of the participating centres in Paris and Amsterdam 
(Hôpital Pitié-Salpêtrière and VU University Medical 
Centre) and informed consent from patients and their 
families. 
Procedures
Exome sequencing was undertaken in the three patients 
with adult-onset disease under the assumption that these 
patients had one disease with autosomal recessive 
inheritance. In patient 3, who has consanguineous 
parents, we identifi ed homozygous regions (appendix), in 
which we searched for homozygous mutations. One 
paediatric patient came from a family with X-linked disease 
inheritance, and this family participated in another exome 
sequencing study focused on X-linked disorders. We then 
used Sanger sequencing to sequence the CLCN2 gene in 
both the adult and paediatric patients; GJB1, which 
encodes the gap junction beta-1 protein (also known as 
connexin 32), was sequenced in the male patient without 
CLCN2 mutations (appendix). 
CLCN2 mRNA was quantifi ed in fi broblasts of adult 
patients with CLCN2 mutations. Transient transfections 
of wild-type or mutant ClC-2-V5-His6 expression 
plasmids in COS7 cells were used to study the functional 
eff ects of CLCN2 mutations (appendix).
To defi ne which cell types express ClC-2 in healthy 
mature human brain, we examined the posterior limb of 
the internal capsule, frontal white matter, frontal cortex, 
and ependyma with fl uorescence immunohistochemistry 
of tissue obtained at autopsy from nine patients aged 
1–75 years (appendix) who succumbed to heart disease or 
extracerebral neoplasm. None of the patients had 
neurological symptoms and neuro pathological 
examination showed no abnormalities.
Immunohistochemistry (appendix) was done on frozen 
tissue using antibodies against ClC-2, GlialCAM, MLC1, 
glial fi brillary acidic protein (GFAP; an astrocyte marker), 
oligodendrocyte transcription factor-2 (OLIG2; an 
oligodendrocyte marker), neuronal nuclear antigen 
(NeuN; a neuronal marker, also known as RBFOX3), 
platelet endothelial cell adhesion molecule-1 (PECAM1; 
an endothelial marker, also known as CD31), and 
phosphorylated and non-phosphorylated neurofi lament 
H (SMI31 and SMI32, respectively; axonal markers). The 
anti-ClC-2 antibodies were validated for specifi city 
(appendix). All sections were counterstained with DAPI 
(4,6-diamidino-2-phenylindole; nuclear staining). 
Electron microscopy was done on tissue from the 
posterior limb of the internal capsule (appendix). 
Sections were incubated with ClC-2, GlialCAM, and 
MLC1 antibodies. 
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding authors had full 
access to all the data in the study and had fi nal 
responsibility for the decision to submit for publication.
Results
Seven patients met our inclusion criteria, three with adult-
onset disease and four with childhood-onset disease. The 
three patients with adult-onset disease were unrelated 
(patients 1–3; table 1). They had mild cerebellar ataxia and 
a variable combination of chorioretinopathy with visual 
fi eld defects, optic neuropathy, and headaches. One 
patient had a schizophrenia-like disorder. The three 
patients with childhood-onset disease and CLCN2 See Online for appendix
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mutations (patients 4–6) had mild cerebellar ataxia and a 
variable combination of mild spasticity, visual fi eld defects, 
learning disabilities, and headaches (table 1).
The patient with X-linked disease (patient 7; table 1) 
presented with nystagmus at 12 months. He developed 
incapacitating cerebellar ataxia and spasticity. Clinical 
evidence of peripheral nerve involvement was absent, 
although recent neurophysiological investigations 
revealed mild motor neuropathy. Aff ected male family 
members had the same clinical and MRI fi ndings. 
Carrier females had no abnormalities.
All patients had prominent signal abnormalities and 
decreased ADC values in the posterior limbs of the 
internal capsules, cerebral peduncles in the midbrain, 
pyramidal tracts in the pons, and middle cerebellar 
peduncles (fi gure 1; appendix). All patients with adult-
onset disease had additional signal abnormalities in 
specifi c brainstem tracts and the cerebellar white matter 
(appendix). Cerebral hemispheric white matter 
abnormalities were mild and non-specifi c. In one patient 
(patient 1), low to borderline-low ADC values were also 
found in cerebral white matter areas (appendix). 
In the paediatric patients, the same additional signal 
abnormalities in specifi c brainstem tracts and cerebellum 
were noted. Additionally, they had diff use mild signal 
abnormality of the brain white matter, which was 
hyperintense relative to grey matter on T2-weighted and T1-
weighted images (fi gure 1). Low to borderline-low ADC 
values were present in the cerebral and cerebellar 
hemispheric white matter and corpus callosum. The signal 
behaviour of the white matter on T1-weighted and T2-
weighted images would typically suggest hypomyelination,29 
but hypomyelination is associated with increased size of 
water spaces and therefore increased ADC values.30 The 
low white matter ADC suggests myelin microvacuolation 
instead of hypo myelination.31 Increased intramyelinic 
water accounts for the mild T2-signal changes. 
As a result of exome sequencing and homozygosity 
mapping in patient 3, we identifi ed ten homozygous 
single nucleotide substitutions and two homozygous 
insertion–deletions with a possible eff ect on gene or 
protein function that were absent from control databases 
(appendix). One was a homozygous in-frame deletion 
(p.Leu144_Ile145del) in CLCN2. Analysis of exome data 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Year of birth 1948 1952 1961 1996 1998 2001 1993
Sex/ancestry f/north Africa f/north Africa f/north Africa f/Europe m/Europe f/Europe m/Europe
Consanguineous parents No No Yes Not known No Yes No
Aff ected family members No No No No No No Yes
Early psychomotor 
development
Normal Normal Normal Normal Normal Normal Normal, but has never 
walked without support
Age at fi rst sign 44 years 57 years 30 years 12 years 6 years 3 years 12 months
Presenting signs Action tremor, 
mild gait ataxia




Headache Action tremor, 
mild gait ataxia
Nystagmus
Disease course Stable Progressive Stable Stable Stable Stable Slowly progressive
Signs of the deterioration None Deafness None None None None Motor deterioration
Headache No No Yes Yes, severe Yes, severe No No
Cognitive level Normal Normal Severe learning disability Mild learning 
disability
Normal Mild learning 
disability
Mild learning disability
Head circumference Normal Normal Normal Normal Normal Borderline 
macrocephaly
Borderline macrocephaly
Vision Normal 20/80 right eye; 
20/400 left eye
1/10 right eye; 1/50 left 
eye
Normal with glasses Normal with glasses, 
strabismus
Normal Normal
Visual fi eld defects No Yes Yes Yes No Yes No
Retina and optic nerve Normal Retinoschisis, 
bilateral optic 
neuropathy
Retinal atrophy, choroidal 
neovascularisation, 
bilateral optic neuropathy
Normal Normal Normal Normal
Nystagmus No No No No Yes No Yes
Hearing Normal Perceptive 
hearing loss
Normal Normal Normal Normal Normal
Spasticity No No No Yes, mild No Yes, mild Yes, prominent
Ataxia Yes, mild Yes, mild Yes, mild Yes, mild Yes, mild Yes, mild Yes, severe
Peripheral polyneuropathy No No No No No No No clinical signs; mildly 
decreased motor NCV 
Gait Unstable Unstable Unstable Unstable Normal Unstable Wheelchair dependent
f=female. m=male. NCV=nerve conduction velocity. 
Table 1: Clinical fi ndings
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in the other adult patients revealed the same homozygous 
non-sense mutation (p.Trp570X) in CLCN2 (table 2; 
appendix). CLCN2 was the only gene that contained at 
least one homozygous or at least two heterozygous, 
possibly deleterious variants in all three patients that 
were absent from exome data from individuals with 
other diseases analysed at the same time (appendix).
Analysis of the coding sequence of CLCN2 by Sanger 
sequencing in the paediatric patients identifi ed 
homozygous or compound-heterozygous CLCN2 
mutations in three patients (table 2; appendix). All 
mutations were predicted to be pathogenic and none was 
present in healthy controls of the same origin or in the 
International Hapmap Project and the 1000  Genomes 
Project databases (appendix).
Sequencing of the exome of the paediatric patient 
without CLCN2 mutations who had an X-linked family 
history revealed a novel missense mutation (p.Pro174Ser) 
in GJB1 (table 2; appendix). This mutation was confi rmed 
in his mother and in one living similarly aff ected male 
family member. 
Quantifi cation of the CLCN2 mRNA in fi broblasts 
from patients and controls by real-time quantitative PCR 
showed that the mRNA with the p.Trp570X mutation 
was substantially downregulated compared with that of 
controls, by contrast with the mRNA with 
p.Leu144_Ile145del (appendix). Treatment with emetine, 
an inhibitor of non-sense mediated decay, rescued the 
mRNA expression, suggesting that p.Trp570X leads to 
degradation of the mutant mRNA, although a substantial 
fraction of the mRNA subsists. We could not confi rm 
the presence of the truncated protein because expression 
of ClC-2 was undetectable in fi broblasts. Transient 
expression of the protein with the p.Trp570X mutation 
in COS7 cells showed that the truncated protein, if 
expressed, has an aberrant localisation restricted to the 
Golgi apparatus (appendix).
BA DC
Adult patient with CLCN2 mutations
FE HG
JI LK




Paediatric patient with GJB1 mutation
Figure 1: MRI of brain in patients 1, 4, and 7
MRI in patient 1 at the age of 63 years (A–H) shows signal abnormalities on 
T2-weighted images (A–D) in the middle cerebellar peduncles (arrow in A), 
midbrain cerebral peduncles (arrow in B), and posterior limbs of the internal 
capsules (arrow in C). Slight signal abnormalities are present in the cerebral white 
matter (D). Diff usion-weighted images (E, F) show high signal in the midbrain 
cerebral peduncles (arrow in E), posterior limbs of the internal capsules 
(arrow in F), and to a lesser extent the posterior subcortical cerebral white matter 
(compare hyperintense posterior white matter to normal anterior white matter in 
E and F), suggesting restricted diff usion, confi rmed by low ADC values on the ADC 
maps (low signal in G and H, arrows). MRI in patient 4 at the age of 14 years (I–P) 
shows diff use mild T2-hyperintensity (I–K) and T1-hyperintensity (L) of all white 
matter structures. Prominent T2-hyperintensity is seen in the basis pontis (I), 
middle cerebellar peduncles (I), midbrain cerebral peduncles (J), and posterior 
limbs of the internal capsules (K). Diff usion-weighted images (M, N) show 
increased signal in virtually all white matter, especially the midbrain cerebral 
peduncles (arrow in M) and posterior limbs of the internal capsules (arrow in N), 
suggesting restricted diff usion, confi rmed by low ADC values on the ADC maps 
(arrows in O and P). MRI in patient 7 at the age of 14 years (Q–X) shows diff use 
mild T2-hyperintensity (Q–S) and T1-hyperintensity (T) of all white matter 
structures. Prominent T2-hyperintensity is seen in the middle cerebellar 
peduncles (Q), midbrain cerebral peduncles (R), and posterior limbs of the internal 
capsules (S). Diff usion-weighted images (U, V) show mildly increased signal in 
almost all white matter, especially the midbrain cerebral peduncles (arrow in U) 
and posterior limbs of the internal capsules (arrow in V), suggesting restricted 
diff usion, confi rmed by low ADC values on the ADC maps (arrows in W and X).
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The p.Leu144_Ile145del and p.Ala500Val mutations are 
thought to aff ect conserved hydrophobic aminoacids 
located in transmembrane domains of ClC-2, possibly 
leading to protein misfolding or misinsertion in the 
membrane. To test this hypothesis, we compared the 
expression and subcellular localisation of V5-His6-tagged 
ClC-2 with the p.Leu144_Ile145del or p.Ala500Val 
mutation to those of the wild-type protein in COS7 cells. 
Localisation of the p.Leu144_Ile145del ClC-2 and 
p.Ala500Val ClC-2 proteins was restricted to the 
endoplasmic reticulum, whereas wild-type ClC-2 was 
present in diff erent subcellular compartments including 
the plasma membrane (fi gure 2A). Additionally, the 
amount of both mutated ClC-2 proteins transiently 
expressed in COS7 cells was lower than the amount of 
wild-type ClC-2 (fi gure 2B) and the mutated proteins 
hardly reached the plasma membrane (fi gure 2C and 2D). 
These fi ndings suggest that p.Leu144_Ile145del ClC-2 
and p.Ala500Val ClC-2 are trapped and degraded in the 
endoplasmic reticulum. Altogether, these results suggest 
that all mutations identifi ed in the patients led to a 
complete or at least partial loss of function of the ClC-2 
channel by diff erent mechanisms. 
Immunohistochemistry of the healthy brain samples 
revealed that virtually all GFAP-positive fi brous astrocytes 
in the posterior limb of the internal capsule and frontal 
white matter express ClC-2 on the surface of cell bodies 
and processes (fi gure 3A). ClC-2 immunopositivity had a 
fi ne punctate quality (fi gure 3A, inset), as expected for a 
membrane protein. Many ClC-2-positive astrocytic 
processes ran parallel and perpen dicular to axonal bundles 
(fi gure 3A) and abutting axons (appendix). ClC-2 was 
enriched in perivascular astrocytes (fi gure 3B), where 
GlialCAM (fi gure 3C; appendix) and MLC1 (appendix) 
were also expressed. GlialCAM and MLC1 
immunoreactivity overlapped consistently and extended 
further distally than ClC-2 into astrocytic endfeet 
approaching the basal lamina (fi gure 3C; appendix). A 
more discrete, punctate ClC-2 immunoreactivity was 
visible intermittently along axons (appendix). We detected 
many ClC-2-positive and GFAP-negative cells with the 
morphology of oligodendrocytes. In the frontal cortex, 
ClC-2 expression was detected only in scattered 
protoplasmic astrocytes around blood vessels and in 
astrocytes that are part of the glia limitans (fi gure 3D; 
appendix). In these locations, ClC-2 astrocytes coexpressed 
GlialCAM (fi gure 3E; appendix) and MLC1 (appendix). 
ClC-2 expression was also detected in the ependymal 
lining, again overlapping with GlialCAM (fi gure 3F; 
appendix) and MLC1 (appendix). No ClC-2-positive 
expression was noted in neuronal perikarya (fi gure 3G). 
Electron microscopy confi rmed that ClC-2 was 
abundantly present in white matter astrocytes and 
enriched in cell processes contacting abaxonal myelin 
(fi gure 4A) and contacting each other (fi gure 4B). At these 
sites, GlialCAM showed a similar distribution (fi gure 4C, 
and 4D). ClC-2 immunoreactivity was also visible inside 
axons and at the axonal surface contacting adaxonal 
myelin (appendix). By contrast, GlialCAM and MLC1 
were not detected in axons or myelin (fi gure 4C). Around 
blood vessels, ClC-2 was found at astrocyte–astrocyte 
contacts in endfeet (fi gure 4B), a site where GlialCAM 
(fi gure 4D) and MLC1 (fi gure 4E) were present. 
Discussion
We showed that autosomal recessive loss-of-function 
mutations in CLCN2 cause a leukoencephalopathy with 
MRI evidence of myelin microvacuolation. These 
fi ndings are similar to those in ClC-2-defi cient mice and 
are in line with the notion that ClC-2 in the brain is 
involved in ion and water homoeostasis (panel).5,6  
Our observations do not support the hypothesis that 
loss-of-function mutations in CLCN2 confer an increased 
risk of epilepsy. None of the six patients with homozygous 
or compound heterozygous mutations in CLCN2 had 
epilepsy or a family history of epilepsy, suggesting that 
partial or complete ClC-2 loss of function per se is 
insuffi  cient to cause epilepsy.
The disease associated with CLCN2 mutations is 
variable in age of onset and clinical presentation. Mild 
Exon DNA RNA Protein Genotype Confi rmation in parents*
CLCN2 mutation
Patient 1 15 c.709G→A ·· p.Trp570X Homozygous ··
Patient 2 15 c.1709G→A ·· p.Trp570X Homozygous ··
Patient 3 4 c.430_435del ·· p.Leu144_Ile145del Homozygous ··









Patient 5 14 c.1499C→T r.1499c→t p.Ala500Val Homozygous Father and mother
Patient 6 8 c.828dupG ·· p.Arg277AlafsX23 Homozygous Father and mother
GJB1 mutation
Patient 7 2 c.520C→T ·· p.Pro174Ser Hemizygous Mother
*This column shows whether the mutation was confi rmed in the father and mother of the aff ected patient. †Comprises a deletion of exons 2–5 and part of exon 6 and the 
insertion of intron 1 c.63+1097_64−1108. 
Table 2: CLCN2 and GJB1 mutations
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cerebellar ataxia is the most consistent fi nding. 
Retinopathy, as reported in the ClC-2-defi cient mice, was 
detected in only some of the patients, although the visual 
fi eld defects in absence of other ophthalmological 
fi ndings suggest that the other patients might have had a 
retinopathy that was too subtle to be picked up at 
funduscopy. ClC-2-defi cient mice are sterile because of 
testicular degeneration; however, the only male patient 
with CLCN2 mutations (aged 15 years) did not yet show 
signs of testicular degeneration. Although the clinical 
presentation of the patients is non-specifi c and does not 
allow a diagnosis, MRI fi ndings in these patients are 
highly specifi c and do allow a diagnosis. We have also 
analysed the CLCN2 gene in several other adult and 
paediatric patients who had similar MRI fi ndings to 
those of study patients, but did not meet the MRI 
inclusion criteria, and we did not fi nd CLCN2 mutations 
in any of them (data not shown). 
The phenotypic variability reported in the patients 
might at least in part be related to the extent of ClC-2 loss 
of function. Both the mutational variation and functional 
analyses suggest loss of function of ClC-2, but some 
Figure 2: Expression and subcellular localisation of wild-type and mutated ClC-2
(A) Subcellular localisation of wild-type (i–vi) and mutated (p.Leu144_Ile145del [vii–xii]; p.Ala500Val [xiii–xviii]) ClC-2 proteins and colocalisation with markers of 
endoplasmic reticulum (anticalreticulin, red, [ii, viii,  xiv]) or plasma membrane (pEYFP-Mem, yellow [v, xi, xvii]) by confocal microscopy. Note that wild-type ClC-2 is 
present at the plasma membrane and diff erent subcellular compartments, whereas both mutant proteins are mainly seen in the endoplasmic reticulum. Scale 
bar=10 μm. (B) Quantifi cation of colocalisation of wild-type or mutated ClC-2 with endoplasmic reticulum and plasma membrane using Pearson’s correlation coeffi  cient, 
including at least three cells per group. (C) Analysis of wild-type and mutated ClC-2 protein expression in whole lysates and plasma membranes by Western blot show 
that the expression of mutant ClC-2 protein transiently expressed in COS7 cells is lower than that of the wild-type protein, especially in the plasma membrane. The image 
shows the result of a representative experiment. Flotillin was used to control and normalise the protein load. (D) Quantifi cation of wild-type and mutant ClC-2 proteins 
present in whole lysates and in plasma membranes shows that, overall, mutant ClC-2 proteins are not as highly expressed as wild-type ClC-2, suggesting that they are 
misfolded and unstable. By contrast with the wild-type form, both mutants are retained in the endoplasmic reticulum where they are probably degraded and hardly 
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mutated proteins, in particular C-terminally truncated or 
missense mutants that reach the plasma membrane in 
substantial amounts, could possibly retain a partial 
function. 
The present study adds to the growing insight into how 
the brain deals with the continuous shifts of ions and 
water related to action potentials. Brain white matter 
mainly consists of myelinated axons and its most 
important physiological function is impulse conduction. 
Action potentials are based on shifts in ions, which are 
obligatorily associated with osmotically driven shifts in 
water, needing rapid compensation. Any disturbance of 
the compensatory mechanisms might disrupt impulse 
transmission or lead to life-threatening changes in brain 
volume. Brain ion and water homoeostasis is complex 
and involves electrolytes and organic osmolytes, channels, 
and transporters, and coordinated processes such as 
regulatory volume decrease and increase to correct cell 
volume changes.32,33 Astrocytes are central in this process. 
They are the most abundant and best connected cell type 
of the so-called panglial syncytium, a vast network of 
astrocytes, oligodendrocytes, and ependymal cells 
interconnected by gap junctions. The panglial syncytium 
is essential for long-distance disposal of ions and water.32,33
Action potentials are associated with disposal of 
submyelinic and intramyelinic potassium.33 In 
myelinated axons, depolarisation is associated with 
infl ux of sodium at nodes of Ranvier; compensatory 
potassium effl  ux occurs in paranodal regions covered by 
myelin (appendix). Gap junctions help to transport 
potassium and osmotic water across myelin layers into 
astrocytes. Connexin 32 constitutes gap junctions in 
paranodal myelin; connexin 32 and connexin 47 
constitute gap junctions between myelin and astrocytes. 
The astrocytic syncytium allows rapid dispersion of 
potassium and buff ers the associated volume changes. 
This process of so-called potassium siphoning prevents 
action-potential-induced osmotic intramyelinic 
oedema.33 Disruptions of molecular components of 
these ion and water homoeostatic pathways are 
associated with intramyelinic oedema in human diseases 
and mutant mouse models.6,19,33–35 No myelin vacuolation 
occurs in mouse models in the absence of action 
potentials,6,34 showing that hindrance of compensation of 
action-potential-induced ion and water shifts is the main 
factor leading to osmotic intramyelinic oedema.
Insight into the mechanisms and molecular 
components of brain ion and water homoeostatic 
pathways is still incomplete. Our study provides evidence 
that ClC-2 is one of these molecular components. The 
fi rst observation that supports a role of ClC-2 in brain ion 
and water homoeostasis is the MRI evidence of myelin 
microvacuolation in patients with CLCN2 mutations. 
The second observation is the presence of the same MRI 
abnormalities with evidence of myelin microvacuolation 
in a patient with a GJB1 mutation. Mutations in GJB1, 
encoding connexin 32, lead to X-linked Charcot-Marie-
Tooth disease. In addition to peripheral neuropathy, 
patients with X-linked Charcot-Marie-Tooth disease 
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Figure 3: Expression of ClC-2 in a healthy adult human brain
Double immunohistochemical staining of the cerebral white matter for ClC-2 (green) and the astrocyte-specifi c marker 
GFAP (red) shows that all GFAP-positive astrocytes express ClC-2 (A). Note the long ClC-2-positive astrocytic processes 
extending parallel and perpendicular to the direction of the fi bre bundle. ClC-2 shows a punctate immunoreactivity, as 
expected for a membrane protein (inset in A). Colabelling of the same tissue for ClC-2 (green) and the vascular 
endothelial cell marker CD31 (also known as PECAM1; red) shows that expression of ClC-2 is enhanced in the 
astrocytes surrounding the blood vessels deep in the parenchyma (B) and the penetrating vessels at the surface of the 
brain (D). Note the many fi ne astrocytic processes running along the white matter capillary (B). Perivascular astrocytes 
(C), subpial astrocytes (E), and ependymal cells (F) coexpress GlialCAM (red) with ClC-2 (green), but GlialCAM 
immunoreactivity extends further into the astrocytic processes and endfeet (inset in C). Double staining of the frontal 
cortex for ClC-2 (green) and the neuronal marker NeuN (red) shows that, in this location, ClC-2 immunoreactivity is 
restricted to perivascular astrocytes (G). No ClC-2 expression is seen in the NeuN-positive neuronal cells (inset in G). 
In all images the cell nuclei are stained with DAPI (4’,6-diamidino-2-phenylindole; blue). 
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evidence of transient myelin vacuolation.36 We have no 
explanation for why the mutation detected in the family 
that we studied has a persistent eff ect on brain myelin, 
without any fl uctuation, both clinically and on serial 
MRI. The serious spasticity and cerebellar ataxia probably 
over shadow the neuropathy, which was only detected by 
neurophysiological studies after the GJB1 mutation had 
been identifi ed. Other cases of X-linked Charcot-Marie-
Tooth disease with persistent clinical signs of brain 
dysfunction and white matter disease on MRI have been 
reported, but diff usion fi ndings were not mentioned.37 
The third observation supporting the role of ClC-2 in 
brain ion and water homoeostasis is the ClC-2 mem-
brane expression in the panglial syncytium, with 
enhanced expression around blood vessels, in the glia 
limitans, ependymal lining, and astrocyte–astrocyte 
contacts in the white matter. The fourth observation is 
the fi nding that ClC-2 colocalises with MLC1 and 
GlialCAM in astrocytic endfeet at the perivascular basal 
lamina and glia limitans.26,27,38 As recently reviewed,22 both 
GLIALCAM and MLC1 mutations cause megalen-
cephalic leukoencephalopathy with subcortical cysts,23,26 a 
disease characterised by myelin vacuolation in the 
cerebral white matter, in which the corpus callosum, 
internal capsule, brainstem, and cerebellum are spared 
in comparison.20,21 MLC1 is involved in chloride currents 
necessary for the astrocytic regulatory volume decrease 
after cell swelling.39 GlialCAM is indispensable for 
correct localisation of MLC1 and ClC-2.26,27 Results of our 
study suggest that ClC-2 is part of the same ion and water 
homoeostatic pathways as MLC1 and GlialCAM 
(appendix). 
A limitation of our study is the rather small number 
of patients. The database on unclassifi ed leukoen-
cephalopathies in Amsterdam contains more than 
3000 patients, but only a few patients fulfi lled the MRI 
criteria. It could be that the ClC-2-related leuko-
encephalopathy is very rare, but we cannot exclude the 
possibility that the phenotypic variation is much wider 
and that we have not analysed a suffi  cient number of 
patients yet. Another issue is the specifi city of the 
antibody against human ClC-2. To provide full proof, 
absence of all staining should be shown in brain tissue of 
a patient with two CLCN2 null mutations. This tissue is 
not available. However, we did several experiments that 
support the specifi city of the antibody and thus the 
validity of the immunohistochemical data (appendix).
Many questions remain. The exact role of ClC-2 in 
brain ion and water homoeostasis is unknown. Why 
defects in the same pathways cause diff erent white matter 
disorders is unclear. ClC-2-related and connexin-32-
related diseases preferentially aff ect white matter 
structures that are spared (relatively) by MLC1-related and 
GlialCAM-related disease. Although recessive mutations 
in MLC1 and GLIALCAM lead to diff use cerebral white 
matter oedema, sparing the corpus callosum, internal 
capsule, brainstem, and cerebellum, recessive mutations 
in CLCN2 and GJB1 preferentially cause white matter 
oedema of the internal capsule, brainstem structures, and 
cerebellum. Another intriguing question concerns the 
size of the myelin vacuoles. In MLC, ADC values in the 
aff ected white matter are highly increased,40 suggesting 
large vacuoles and increased extracellular spaces, as 
confi rmed by electron microscopy.21 In ClC-2-related and 
connexin-32-related disease, ADC values in aff ected white 
matter are low, suggesting small intramyelinic vacuoles 
and extracellular spaces. Although GlialCAM is supposed 
to be a chaperone for both MLC1 and ClC-2,26,27 recessive 
GLIALCAM mutations lead to a disease that is 
indistinguishable from the disease caused by MLC1 
mutations and does not share the MRI features of the 
disease caused by CLCN2 mutations.26 We noted that 
GlialCAM and MLC1 share restricted localisation in distal 
astrocytic processes, whereas ClC-2 has a more diff use 
membrane localisation in astrocytes. These disease 
observations suggest that GlialCAM is a straightforward 
chaperone for MLC1, but that its relation with ClC-2 is 
more complex.
The growing group of known disorders aff ecting brain 
ion and water homoeostasis are typically relatively mild 
compared with other brain disorders, both in mice5,6,19,35 
and human beings.20,24,26,36 The importance of the volume 


























Figure 4: ClC-2, GlialCAM, and MLC1 immunoreactivity in healthy adult white matter 
By use of electron microscopy, expression of ClC-2 is detected in astrocytic processes in between myelinated axons 
(A) and in contact with abaxonal myelin (inset in A). A similar localisation is observed for GlialCAM (C). Intense 
ClC-2 immunoreactivity is present in astrocytic endfeet surrounding blood vessels (B). Note the enhanced ClC-2 
expression in the astrocyte–astrocyte contacts of the endfeet (B). At this site, GlialCAM (D) and MLC1 (E) are also 
expressed. ast=astrocyte. bm=basement membrane. m=myel in.
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observation that it does not rely on just one protein or 
one pathway. Mutations in one protein only lead to 
partial and sometimes transient dysfunction. It is 
important to note that intramyelinic oedema can be 
reversible. Patients with megalencephalic leuko en ce-
phalopathy with subcortical cysts, caused by dominant 
GLIALCAM mutations, improve or recover 
spontaneously.24,26 In most patients with a GJB1 mutation, 
the white matter disease is transient.36 If means are 
found to target components of the ion and water 
homoeostatic pathways, myelin oedema might be 
successfully combated.
Contributors
CDe, MB, CDu, NP, CvB, EP, and TEMA did the experiments or 
analysed the data (or both). CDe, FS, and MSvdK designed and 
supervised the study. CDe and MSvdK wrote the fi rst draft of the 
manuscript. DG, VT, ET, FD, AB, CEdD-S, JSV, AV, GU, CY, SGF, VMK, 
JK, MK, and NIW contributed to patient data or contributed materials 
essential to the study (or both). All coauthors critically reviewed and 
approved the last version of the manuscript.
Panel: Research in context
Systematic review
We searched PubMed and Online Mendelian Inheritance in 
Man with the search terms “leukoencephalopathy”, “MLC”, 
“MLC1”, “HepaCAM”, “GlialCAM”, “ClC-2”, “CLCN2”, ”X-linked 
Charcot Marie Tooth”, ”connexin 32”, and ”GJB1”, for articles 
in the English language published between 1969 and Dec 31, 
2012. We also searched reference lists of identifi ed papers. We 
studied reports on epilepsy and leukoencephalopathy related 
to mutations in the genes CLCN2, MLC1, GLIALCAM, and GJB1, 
both in mice and humans.  Whole-exome sequencing is a well 
established and eff ective strategy to identify the gene 
mutated in several patients with the same disease with 
autosomal recessive and X-linked recessive inheritance. For 
interpretation of our molecular genetic fi ndings we used 
Alamut2.1 (Interactive Biosoftware), 1000 Genomes, and 
HapMap databases.
Interpretation
The fi ndings of our study, when added to those of previous 
work, suggest that there is no evidence for a role of CLCN2 
mutations in epilepsy, which should put a defi nitive end to 
the discussion. By contrast, following on from fi ndings in 
rodents, our results show that ClC-2 is involved in brain ion 
and water homoeostasis in human beings. Defects in MLC1, 
GlialCAM, connexin 32, and ClC-2 all lead to 
leukoencephalopathies characterised by intramyelinic 
oedema. Observations in X-linked Charcot-Marie-Tooth 
disease caused by GJB1 mutations, and megalencephalic 
leukoencephalopathy with subcortical cysts caused by 
dominant GLIALCAM mutations, show that intramyelinic 
oedema can be reversible. If means are found to target 
components of the ion and water homoeostatic pathways, 
this oedema could be successfully combated. Our study 
shows that ClC-2 is one of the molecular components, and 
might be a potential therapeutic target.
Confl icts of interest
We declare that we have no confl icts of interest.
Acknowledgments
We thank patients and families for their participation in the study. We 
thank the following practitioners for their identifi cation and referral of 
patients: Janell Kierstein, Johan van Hove, and Abigail Collins from the 
Children’s Hospital of Denver, and Johanna L Schmidt, Children’s 
National Medical Center, Washington. We thank Raúl Estévez, University 
of Barcelona, for the anti-MLC1 antibody, and the Dutch Brain Bank for 
providing part of the tissue used in the study. We thank 
James M Powers, University of Rochester, for critical reading of the 
manuscript. We thank the PIC-PS platform of Centre de Recherche de 
l’Institut du Cerveau et de la Moelle Epinière (CRICM) and the 
genotyping and sequencing platform of L’Institut du Cerveau et de la 
Moelle Épinière for technical assistance; the DNA and cell bank of 
CRICM for DNA extraction and cell culture; Kees van Rozendaal, 
Department of Clinical Genomics, Maastricht University Medical Center, 
for assistance in the exome sequencing of patient 7 and his family; and 
Petra J W Pouwels, VU University Medical Center, Amsterdam, for her 
help with the analysis of the apparent diff usion coeffi  cient maps.
References
1 Planells-Cases R, Jentsch TJ. Chloride channelopathies. 
Biochim Biophys Acta 2009; 1792: 173–89.
2 Thiemann A, Grunder S, Pusch M, Jentsch TJ. A chloride channel 
widely expressed in epithelial and non-epithelial cells. Nature 1992; 
356: 57–60.
3 Grunder S, Thiemann A, Pusch M, Jentsch TJ. Regions involved in 
the opening of CIC-2 chloride channel by voltage and cell volume. 
Nature 1992; 360: 759–62.
4 Jordt SE, Jentsch TJ. Molecular dissection of gating in the ClC-2 
chloride channel. EMBO J 1997; 16: 1582–92.
5 Bosl MR, Stein V, Hubner C, et al. Male germ cells and 
photoreceptors, both dependent on close cell-cell interactions, 
degenerate upon ClC-2 Cl(-) channel disruption. EMBO J 2001; 
20: 1289–99.
6 Blanz J, Schweizer M, Auberson M, et al. Leukoencephalopathy 
upon disruption of the chloride channel ClC-2. J Neurosci 2007; 
27: 6581–89.
7 Sik A, Smith RL, Freund TF. Distribution of chloride 
channel-2-immunoreactive neuronal and astrocytic processes in the 
hippocampus. Neuroscience 2000; 101: 51–65.
8 Smith RL, Clayton GH, Wilcox CL, Escudero KW, Staley KJ. 
Diff erential expression of an inwardly rectifying chloride 
conductance in rat brain neurons: a potential mechanism for 
cell-specifi c modulation of postsynaptic inhibition. J Neurosci 1995; 
15: 4057–67.
9 Rinke I, Artmann J, Stein V. ClC-2 voltage-gated channels constitute 
part of the background conductance and assist chloride extrusion. 
J Neurosci 2010; 30: 4776–86.
10 Ratte S, Prescott SA. ClC-2 channels regulate neuronal excitability, 
not intracellular chloride levels. J Neurosci 2011; 31: 15838–43.
11 D’Agostino D, Bertelli M, Gallo S, et al. Mutations and 
polymorphisms of the CLCN2 gene in idiopathic epilepsy. Neurology 
2004; 63: 1500–02.
12 Stogmann E, Lichtner P, Baumgartner C, et al. Mutations in the 
CLCN2 gene are a rare cause of idiopathic generalized epilepsy 
syndromes. Neurogenetics 2006; 7: 265–68.
13 Everett K, Chioza B, Aicardi J, et al. Linkage and mutational 
analysis of CLCN2 in childhood absence epilepsy. Epilepsy Res 2007; 
75: 145–53.
14 Saint-Martin C, Gauvain G, Teodorescu G, et al. Two novel CLCN2 
mutations accelerating chloride channel deactivation are associated 
with idiopathic generalized epilepsy. Hum Mutat 2009; 30: 397–405.
15 Combi R, Grioni D, Contri M, et al. Clinical and genetic familial 
study of a large cohort of Italian children with idiopathic epilepsy. 
Brain Res Bull 2009; 79: 89–96.
16 Kleefuss-Lie A, Friedl W, Cichon S, et al. CLCN2 variants in 
idiopathic generalized epilepsy. Nat Genet 2009; 41: 954–55.
17 Haug K, Warnstedt M, Alekov AK, et al. Retraction: Mutations in 
CLCN2 encoding a voltage-gated chloride channel are associated 
with idiopathic generalized epilepsies. Nat Genet 2009; 41: 1043.
For the 1000 Genomes 
database see http:// 
www.1000genomes.org
For HapMap see http://www.
hapmap.org
Articles
668 www.thelancet.com/neurology   Vol 12   July 2013
18 Niemeyer MI, Cid LP, Sepulveda FV, et al. No evidence for a role of 
CLCN2 variants in idiopathic generalized epilepsy. Nat Genet 2010; 
42: 3.
19 Edwards MM, Marin de Evsikova C, Collin GB, et al. Photoreceptor 
degeneration, azoospermia, leukoencephalopathy, and abnormal 
RPE cell function in mice expressing an early stop mutation in 
CLCN2. Invest Ophthalmol Vis Sci 2010; 51: 3264–72.
20 van der Knaap MS, Barth PG, Stroink H, et al. 
Leukoencephalopathy with swelling and a discrepantly mild clinical 
course in eight children. Ann Neurol 1995; 37: 324–34.
21 van der Knaap MS, Barth PG, Vrensen GF, Valk J. Histopathology 
of an infantile-onset spongiform leukoencephalopathy with a 
discrepantly mild clinical course. Acta Neuropathol 1996; 92: 206–12.
22 van der Knaap MS, Boor I, Estévez R. Megalencephalic 
leukoencephalopathy with subcortical cysts: chronic white matter 
oedema due to a defect in brain ion and water homoeostasis. 
Lancet Neurol 2012; 11: 973–85.
23 Leegwater PA, Yuan BQ, van der Steen J, et al. Mutations of MLC1 
(KIAA0027), encoding a putative membrane protein, cause 
megalencephalic leukoencephalopathy with subcortical cysts. 
Am J Hum Genet 2001; 68: 831–38.
24 van der Knaap MS, Lai V, Kohler W, et al. Megalencephalic 
leukoencephalopathy with cysts without MLC1 defect. Ann Neurol 
2010; 67: 834–37.
25 Scheper GC, van Berkel CG, Leisle L, et al. Analysis of CLCN2 as 
candidate gene for megalencephalic leukoencephalopathy with 
subcortical cysts. Genet Test Mol Biomarkers 2010; 14: 255–57.
26 Lopez-Hernandez T, Ridder MC, Montolio M, et al. Mutant 
GlialCAM causes megalencephalic leukoencephalopathy with 
subcortical cysts, benign familial macrocephaly, and macrocephaly 
with retardation and autism. Am J Hum Genet 2011; 88: 422–32.
27 Jeworutzki E, Lopez-Hernandez T, Capdevila-Nortes X, et al. 
GlialCAM, a protein defective in a leukodystrophy, serves as a 
ClC-2 Cl(-) channel auxiliary subunit. Neuron 2012; 73: 951–61.
28 van der Knaap MS, Breiter SN, Naidu S, Hart AA, Valk J. Defi ning 
and categorizing leukoencephalopathies of unknown origin: MR 
imaging approach. Radiology 1999; 213: 121–33.
29 Schiff mann R, van der Knaap MS. Invited article: an MRI-based 
approach to the diagnosis of white matter disorders. Neurology 2009; 
72: 750–59.
30 Dreha-Kulaczewski SF, Brockmann K, Henneke M, et al. 
Assessment of myelination in hypomyelinating disorders by 
quantitative MRI. J Magn Reson Imaging 2012; 36: 1329–38.
31 Patay Z. Diff usion-weighted MR imaging in leukodystrophies. 
Eur Radiol 2005; 15: 2284–303.
32 Benfenati V, Ferroni S. Water transport between CNS 
compartments: functional and molecular interactions between 
aquaporins and ion channels. Neuroscience 2010; 168: 926–40.
33 Rash JE. Molecular disruptions of the panglial syncytium block 
potassium siphoning and axonal saltatory conduction: pertinence to 
neuromyelitis optica and other demyelinating diseases of the 
central nervous system. Neuroscience 2010; 168: 982–1008.
34 Neusch C, Rozengurt N, Jacobs RE, Lester HA, Kofuji P. Kir4.1 
potassium channel subunit is crucial for oligodendrocyte 
development and in vivo myelination. J Neurosci 2001; 21: 5429–38.
35 Menichella DM, Majdan M, Awatramani R, et al. Genetic and 
physiological evidence that oligodendrocyte gap junctions 
contribute to spatial buff ering of potassium released during 
neuronal activity. J Neurosci 2006; 26: 10984–91.
36 Paulson HL, Garbern JY, Hoban TF, et al. Transient central nervous 
system white matter abnormality in X-linked Charcot-Marie-Tooth 
disease. Ann Neurol 2002; 52: 429–34.
37 Siskind C, Feely SM, Bernes S, Shy ME, Garbern JY. Persistent CNS 
dysfunction in a boy with CMT1X. J Neurol Sci 2009; 279: 109–13.
38 Boor PK, de Groot K, Waisfi sz Q, et al. MLC1: a novel protein in 
distal astroglial processes. J Neuropathol Exp Neurol 2005; 
64: 412–19.
39 Ridder MC, Boor I, Lodder JC, et al. Megalencephalic 
leucoencephalopathy with cysts: defect in chloride currents and cell 
volume regulation. Brain 2011; 134: 3342–54.
40 van der Voorn JP, Pouwels PJ, Hart AA, et al. Childhood white 
matter disorders: quantitative MR imaging and spectroscopy. 
Radiology 2006; 241: 510–17.
